ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer

Songnan Wang, Volker Böhnert, Alby J. Joseph, Valentino Sudaryo, Gemini Skariah, Jason Swinderman, Feiqiao Brian Yu, Vishvak Subramanyam, Denise M. Wolf, Xuchao Lyu, Luke A. Gilbert, Laura J. van’t Veer, Hani Goodarzi, Lingyin LiProceedings of the National Academy of Sciences 2023 · DOI

TL;DR

This study identifies ENPP1 as a critical "innate immune checkpoint" in breast cancer, showing that it suppresses the anti-tumor STING pathway by degrading extracellular cGAMP. Inhibiting ENPP1's cGAMP-hydrolyzing activity not only halts tumor growth and metastasis in mice but also predicts patient response to immunotherapy, suggesting ENPP1 blockade as a promising therapeutic strategy.

What Problem Does This Paper Address?

Despite the success of adaptive immune checkpoint inhibitors (ICIs) like anti-PD-1, a significant portion of cancer patients do not respond, particularly those with "cold" tumors lacking immune cell infiltration. This resistance is often linked to the failure of the innate immune system to detect and signal cancer presence. The STING pathway is a key innate immune sensor for cancer-associated DNA, which triggers anti-tumor immunity. However, the mechanisms by which cancer cells evade this innate detection, especially through extracellular signals, are not fully understood. Specifically, the role of ENPP1, an enzyme known to degrade extracellular cGAMP (a STING activator), in this process, and whether its primary function is cGAMP hydrolysis or other enzymatic activities, remained unclear. This paper aims to elucidate the precise role of ENPP1 in breast cancer progression and metastasis, focusing on its impact on the cGAMP-STING pathway and its potential as a therapeutic target.

Methods

The researchers employed a multi-pronged approach:

  • Single-cell RNA sequencing (scRNA-seq): This was a core technique used to comprehensively analyze the tumor microenvironment (TME) in mouse models. It allowed them to identify different cell types, their gene expression profiles, and how ENPP1 overexpression affected these populations and their functions.
  • Genetically Modified Mouse Models: They utilized mice with ENPP1 knockout (KO) and mice expressing a catalytically dead ENPP1 mutant (ENPP1 T238A-OE) to dissect the specific roles of ENPP1's catalytic activity, particularly its cGAMP hydrolysis function.
  • Orthotopic Tumor Implantation and Metastasis Models: Standard mouse models were used to study primary tumor growth and the development of lung metastases.
  • In Vivo CGAMP Depletion: They used neutralizing STING protein to specifically block extracellular cGAMP and assess its impact on tumor growth and immune responses.
  • Human Clinical Trial Data Analysis: Data from the ISPY 2 breast cancer clinical trial was analyzed to correlate ENPP1 expression with patient immune status, treatment response (pathological complete response, pCR), and long-term outcomes (distant metastasis-free survival, DMFS) after neoadjuvant anti-PD-1 therapy.

Datasets

  • METABRIC Database: Used to analyze the correlation between ENPP1 mRNA expression and disease-free survival in human breast cancer patients.
  • ISPY 2 Breast Cancer Clinical Trial Data: This dataset was crucial for evaluating ENPP1's predictive value in human patients receiving neoadjuvant immunotherapy (Pembrolizumab and Veliparib + Carboplatin). The data included immune status, treatment response (pCR), and distant metastasis-free survival (DMFS).

Key Insights and Ideas

  • ENPP1 as a "Master Switch" for Metastasis: The study strongly suggests that ENPP1 acts as a critical gatekeeper, determining whether breast cancer progresses to metastasis. Its presence effectively silences the anti-tumor STING pathway.
  • Catalytic Activity is Key: The research definitively shows that ENPP1's ability to hydrolyze cGAMP is its primary mechanism for promoting tumor growth and metastasis, rather than other potential enzymatic activities. This was demonstrated by the catalytically dead mutant phenocopying the effects of ENPP1 knockout.
  • Dual Role of ENPP1 in the TME: ENPP1 doesn't just act on cancer cells; it also suppresses the STING pathway in host immune cells (like macrophages and fibroblasts) within the tumor microenvironment, creating a double-pronged attack against anti-tumor immunity.
  • ENPP1 as a Predictive Biomarker: ENPP1 expression levels in pre-treatment tumor biopsies are a powerful predictor of patient response to anti-PD-1 immunotherapy and long-term survival, highlighting its clinical relevance.
  • Therapeutic Potential of ENPP1 Inhibition: Blocking ENPP1's cGAMP hydrolysis activity offers a promising strategy to "awaken" the innate immune system, specifically by restoring paracrine cGAMP-STING signaling, and could synergize with existing immunotherapies.

Key Results

  • Mouse Models:
    • Loss of ENPP1 function (either through knockout or a catalytically dead mutant) significantly slowed primary tumor growth and abolished metastasis in mouse models.
  • Selective inhibition of ENPP1's cGAMP hydrolysis activity phenocopied the effects of complete ENPP1 knockout, confirming its critical role.
  • scRNA-seq revealed that ENPP1 overexpression suppressed the infiltration of key immune cells (cDC1s, T cells, NK cells, B cells) and promoted immunosuppressive macrophage polarization.
  • ENPP1 deficiency led to increased STING activation in immune cells, correlating with reduced tumor growth.
  • Human Data:
    • Patients with "immune-positive" breast tumors (indicating a more active immune response) had significantly lower ENPP1 mRNA expression.
  • Low ENPP1 expression in patients treated with Pembrolizumab (anti-PD-1) was associated with a significantly higher chance of pathological complete response (pCR).
  • Crucially, patients with low ENPP1 expression in the Pembrolizumab arm had near 100% distant metastasis-free survival at 7 years, compared to ~85% for high ENPP1 expressors.

Limitations and Future Work

  • Generalizability: While the study focused on breast cancer, the authors suggest that ENPP1's role in immune evasion might be relevant in other "immunologically cold" tumors, particularly those with high myeloid content and fibrosis. Further investigation in other cancer types is warranted.
  • Mechanisms of ENPP1 Induction: The study hints that ENPP1 expression might be inducible by extracellular cGAMP and/or ATP in stromal cells. Future work could explore the specific transcription factors and signaling pathways that induce ENPP1 expression in the TME, which could lead to further diagnostic and therapeutic insights.
  • Therapeutic Strategies: While ENPP1 blockade is proposed as a therapeutic strategy, further research is needed to optimize drug development and clinical trial design, particularly in combination therapies with ICIs. The authors mention that ENPP1 inhibitors are already being developed.

Summary updated

Abstract

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) expression correlates with poor prognosis in many cancers, and we previously discovered that ENPP1 is the dominant hydrolase of extracellular cGAMP: a cancer-cell-produced immunotransmitter that activates the anticancer stimulator of interferon genes (STING) pathway. However, ENPP1 has other catalytic activities and the molecular and cellular mechanisms contributing to its tumorigenic effects remain unclear. Here, using single-cell RNA-seq, we show that ENPP1 in both cancer and normal tissues drives primary breast tumor growth and metastasis by dampening extracellular 2'3'-cyclic-GMP-AMP (cGAMP)-STING-mediated antitumoral immunity. ENPP1 loss-of-function in both cancer cells and normal tissues slowed primary tumor growth and abolished metastasis. Selectively abolishing the cGAMP hydrolysis activity of ENPP1 phenocopied ENPP1 knockout in a STING-dependent manner, demonstrating that restoration of paracrine cGAMP-STING signaling is the dominant anti-cancer mechanism of ENPP1 inhibition. Finally, <i>ENPP1</i> expression in breast tumors deterministically predicated whether patients would remain free of distant metastasis after pembrolizumab (anti-PD-1) treatment followed by surgery. Altogether, ENPP1 blockade represents a strategy to exploit cancer-produced extracellular cGAMP for controlled local activation of STING and is therefore a promising therapeutic approach against breast cancer.
BibTeX
@inproceedings{wang2023enpp,
  author = {Songnan Wang and Volker Böhnert and Alby J. Joseph and Valentino Sudaryo and Gemini Skariah and Jason Swinderman and Feiqiao Brian Yu and Vishvak Subramanyam and Denise M. Wolf and Xuchao Lyu and Luke A. Gilbert and Laura J. van’t Veer and Hani Goodarzi and Lingyin Li},
  title = {{ENPP1 is an innate immune checkpoint of the anticancer cGAMP–STING pathway in breast cancer}},
  booktitle = {Proceedings of the National Academy of Sciences},
  year = {2023},
  doi = {10.1073/pnas.2313693120},
}
Figure